Trial Profile

A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Oct 2023 Results of pooled post hoc analysis ((n = 1328, from two phase III trials, ECZTRA 1 and 2) assessing the impact of tralokinumab versus placebo on other clinically meaningful parameters in patients not achieving IGA 0/1 at week 16 published in the American Journal of Clinical Dermatology
08 Sep 2023 Results of pooled analysis from ECZTRA 1 and 2 , exploring the long-term efficacy of tralokinumab for AD, published in the American Journal of Clinical Dermatology
23 Aug 2023 Results of pooled post hoc analysis from ECZTRA 1 and 2 and ECZTRA 3 assessing assess safety published in the JAMA Dermatology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com